Mixed protocol for treatment of infertility
A personalized dosing protocol for rFSH and HP-hMG in ART based on age and body weight addresses the limitations of AMH-based methods, reducing OHSS risk and enhancing treatment outcomes in controlled ovarian stimulation.
Patent Information
- Application Number
- PCT/EP2026/063014
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Existing assisted reproductive technology (ART) protocols for controlled ovarian stimulation (COS) face challenges in predicting ovarian response, leading to risks of ovarian hyperstimulation syndrome (OHSS) and require AMH assays that are not universally accepted, necessitating improved methods for personalized dosing of gonadotropins like rFSH and hMG.
A mixed protocol personalizes the starting dose of rFSH and HP-hMG based on age and body weight, avoiding AMH-based dosage, with specific dosing regimens for different age and weight groups, and adjusting doses based on serum estradiol levels during stimulation.
This approach reduces the risk of OHSS and achieves results comparable to AMH-based protocols without the need for AMH assays, improving safety and efficacy in ART treatments.
Smart Images

Figure IMGF000025_0001_TABLE 
Figure IMGF000027_0001_TABLE 
Figure IMGF000028_0001_TABLE
Abstract
Description
[0001] Mixed Protocol for Treatment of Infertility
[0002] The present invention relates to pharmaceutical products and methods for the treatment of infertility.
[0003] Background
[0004] Assisted reproductive technologies (ART) such as in vitro fertilisation (IVF) are well known. ART generally requires a step of controlled ovarian stimulation (COS), in which a cohort of follicles is stimulated to full maturity. Standard COS regimens include administration of gonadotrophins, such as menotropin (e.g., human menopausal gonadotropin (hMG)) and follicle stimulating hormone (FSH) alone or in combination with luteinising hormone (LH) activity to stimulate multiple follicular development. Usually COS requires administration of a GnRH analogue (GnRH agonist) or GnRH antagonist prior to and / or during stimulation to prevent a premature LH surge which may induce ovulation before planned oocyte retrieval. The aim of COS is generally to stimulate a number of follicles to maturity so, when ovulation is triggered, several oocytes are retrieved for fertilization. In general, the best oocytes are selected for implantation while others may be cryopreserved for future use.
[0005] In case of a too high ovarian response, COS can be associated with a risk of ovarian hyperstimulation syndrome (OHSS), which can lead to cancellation of the COS cycle and can become life threatening in severe cases. The ability to predict the ovarian response potential of women to COS may allow the development of personalised or individualised COS protocols. Such individualised protocols could, for example, reduce the risk of OHSS in women predicted to have an excessive ovarian response to COS, and prevent cancellation of COS cycles. Levels of anti-Mullerian hormone (AMH) are directly correlated with the ovarian response to gonadotrophins during COS. Thus, high levels of AMH are a good predictor of excessive ovarian response, and an indicator of risk of OHSS, whereas low levels of AMH predict a poor ovarian response to COS. Other predictors of ovarian response include age, body mass index (BMI), FSH, and antral follicle count (AFC).
[0006] The present applicants have developed a human cell line-derived recombinant FSH which is the subject of International Patent Application No. PCT / GB2009 / 000978, published as WO2009 / 127826A, and is approved by the European Commission for the treatment of infertility as REVOKELLE® (follitropin delta). The administration of follitropin delta is personalized according to the patient's ovarian response profile. A specific dosing algorithm, tailored to the pharmacokinetic and pharmacodynamic profile of this follitropin, is utilized. This algorithm takes into account the patient’s body weight, which influences drug exposure, and the level of AMH, which serves as a predictor of ovarian response.In humans, FSH and LH work in concert to stimulate folliculogenesis and ovulation. Therefore, these gonadotropins are typically used for COS in order to increase the number of oocytes produced in IVF. This FSH - LH combination concept has led to so-called “mixed protocols” of concomitant treatment with hMG and FSH for ovarian stimulation being widely used. Indeed, COS protocols that utilize both hMG (a source of both FSH and LH activity) and FSH are commonly used in an attempt to obtain better quality oocytes and embryos and thus, higher pregnancy rates compared to the use of recombinant FSH alone. Determination of a stimulation protocol and FSH dosage typically is established by the physician on the basis of various parameters, which may include various combinations of the patient’s age, body weight and ovarian reserve profile (AMH, AFC, BMI etc.).
[0007] In one mixed protocol study [the Menopurand Rekovelle Combined Study (MARCS)], it was shown that the combination of follitropin delta (rFSH) and highly purified human menopausal gonadotropin (HP-hMG) resulted in a higher number of oocytes retrieved and improved blastulation rates, leading to a greater number of high-quality blastocysts, compared to the administration of follitropin delta alone. In both arms of this MARCS study, the administration of follitropin delta was personalized using the dosing algorithm which takes into account the patient’s body weight and their level of AMH. The maximum daily dose of follitropin delta in both arms of the MARCS study, according to the personalized dosing algorithm, was capped at 12 pg (see discussion in Example 1).
[0008] However, AMH is not utilized or allowed in some countries and clinics as a predictive element for ovarian response to stimulation. Further, dosage based on AMH requires a specific assay prior to treatment. There is a need for improved ART methods, particularly improved mixed hMG and FSH protocols, which reduce risk of OHSS while avoiding dosage based on AMH.
[0009] Summary
[0010] The present applicants have developed a mixed protocol which personalizes the starting dose of both rFSH (follitropin delta) and HP-hMG based on both age and body weight. It is expected that personalizing the dosing of rFSH and HP-hMG by considering both body weight and age could yield results similar or better to those achieved with a mixed protocol dosing regimen based on body weight and AMH. A further advantage of the proposed new protocol is that it avoids dosage of rFSH based on assessment of AMH level, which (a) requires a specific assay prior to treatment, and (b) is not utilized or allowed in some countries and clinics as a predictive element for ovarian response to stimulation when personalising FSH dosages.In accordance with some aspects of the invention, there is provided a composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 17.5 pg (e.g. 14 to 17 pg, e.g. 15 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 200 III to 250 III HP-hMG per day if the patient is of weights 100 kg.
[0011] In accordance with some aspects of the invention, there is provided a composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 200 III to 250 III HP-hMG per day if the patient is of weight > 100 kg. The composition or product may be for administration at a rFSH dose of 15 pg recombinant FSH per day and a menotropin dose of 125 III to 175 III HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of 200 III to 250 III HP-hMG per day if the patient is of weight > 100 kg. The composition or product may be for administration at a rFSH dose of 15 pg recombinant FSH per day and a menotropin dose of 150 III HP-hMG per day if the patient is of weight < 100 kg; ora menotropin dose of 225 III HP-hMG per day if the patient is of weight > 100 kg.
[0012] The use may comprise a step of determining the age of the patient, and a step of administering the rFSH and menotropin (hMG) to a patient of age > 35 years, for example age 35 - 40 years, and or age >40 years. The treatment of infertility may include a step of identifying a patient of age > 35 years and bodyweight < 100 kg or > 100 kg for treatment.
[0013] In accordance with some aspects of the invention, there is provided a composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 14 pg (e.g. 11.5 to 13.5 pg , e.g. 12 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 37.5 III to 100 III HP-hMG per day if the patient is of weight< 100 kg ora menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weights 100 kg.
[0014] According to some aspects there is provided a composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 13 pg (e.g.
[0015] 11.5 to 12.5 pg , e.g. 12 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 37.5 III to 100 III HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weight > 100 kg. The composition or product may be for administration at a rFSH dose of 12 pg recombinant FSH per day and a menotropin dose of 37.5 III to 100 III HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of 125 III to 175 III HP-hMG per day if the patient is of weights 100 kg. The composition or product may be for administration at a rFSH dose of 12 pg recombinant FSH per day and a menotropin dose of 75 III HP-hMG per day if the patient is of weight < 100 kg; or a menotropin dose of 150 III HP-hMG per day if the patient is of weight > 100 kg.
[0016] The use may comprise a step of determining the age of the patient, and a step of administering the rFSH and menotropin (hMG) to a patient of age < 34 years, for example age 28 - 34 years, for example age 30 - 33 years. The treatment of infertility may include a step of identifying a patient of age < 34 years and bodyweight < 100 kg or > 100 kg for treatment.
[0017] The following applies to all aspects of the invention.
[0018] The treatment of infertility may be by means of controlled ovarian stimulation. The treatment of infertility may be by treating a female.
[0019] Preferably, the recombinant human follicle stimulating hormone (rFSH) includes a2,3- and a2,6-sialylation. The recombinant human follicle stimulating hormone (rFSH) may be produced or expressed in a human cell line, optionally wherein the human cell line is modified with an a2,3-sialyltransferase or an a2,6-sialyltransferase. The recombinant human follicle stimulating hormone (rFSH) may include a2,3- and a2,6-sialylation wherein 10 to 20% of the sialylation is a2,6-sialylation and 80 to 90% of the sialylation is a2,3-sialylation (e.g., follitropin delta, available from Ferring B.V.). The recombinant human follicle stimulating hormone (rFSH) may include a2,3- and a2,6-sialylation wherein 10 to 60% of the sialylation is a2,6-sialylation and 40 to 90% of the sialylation is a2,3-sialylation.
[0020] Preferably, the menotropin is highly purified menotropin (HP-hMG).The use may further comprise a step or steps of determining the serum estradiol (E2) level of the patient during treatment / stimulation. The serum estradiol (E2) level of the patient may be determined for the purposes of monitoring the response to stimulation and subsequently adjusting the dose per day dose of menotropin and / or for the choice of triggering medication for final follicular maturation as described in more detail below. The serum estradiol (E2) levels may be determined by methods known in the art.
[0021] The composition or product may be administered from day 1 of stimulation to at least day 5, 6 or 7 of stimulation. From day 6, 7 or 8 of stimulation, the rFSH dose may be maintained, increased or decreased based on the serum estradiol (E2) level of the patient on day 5, 6 or 7 of stimulation. The composition or product may be for use wherein (a) from day 6, 7 or 8 of stimulation, the rFSH dose is (i) decreased (relative to the starting dose) by up to 3 pg (for example decreased by 1 , 2 or 3 pg) in a patient having an estradiol (E2) level of >3000 pmol / L on day 5, 6 or 7 of stimulation; or (b) from day 6, 7 or 8 of stimulation, the rFSH dose is (i) increased (relative to the starting dose) by up to 3 pg (for example increased by 1 , 2 or 3 pg) in a patient having an estradiol (E2) level of <1000 pmol / L, for example 750-999 pmol / L on day 5, 6 or 7 of stimulation; or (c) from day 6, 7 or 8 of stimulation the rFSH dose is maintained in a patient having an estradiol (E2) level of between 1000 and 3000 pmol / L on day 5, 6 or 7 of stimulation.
[0022] The rFSH dose (e.g. the dose from day 6, 7 or 8 of stimulation) may be maintained or further adjusted (further increased or further decreased). In aspects, the daily rFSH dose may be further increased (relative to the starting or previously adjusted dose) by up to 3 pg (for example increased by 1 , 2 or 3 pg) with dose increases implemented not more frequently than once every 2 days. In aspects, the daily rFSH dose may be further decreased (relative to the starting or previously adjusted dose) by up to 3 pg (for example decreased by 1 , 2 or 3 pg).
[0023] In aspects, the maximum rFSH dose is, or is equivalent to, 18 pg recombinant FSH per day. In aspects of the invention, the minimum rFSH dose is, or is equivalent to, 6 pg recombinant FSH per day.
[0024] The use may comprise a further step of assessing follicular growth by ultrasonography e.g., on day 9, 10, 11, 12, 13, 14 etc. of stimulation.
[0025] The use may comprise a further step of triggering ovulation. The further step of triggering ovulation may comprise: administering hCG + / - GnRH agonist to a patient who, following stimulation, has >3 follicles of >17 mm in diameter each and estradiol (E2) levels <10,000 pmol / L; administering hCG + / - GnRH agonist to a patient who, following stimulation, has >3 follicles of>17 mm in diameter each and estradiol (E2) levels between 10,000 pmol / L and 15,000 pmol / L; or administering a GnRH agonist to a patient who, following stimulation, has >20 follicles of >12 mm in diameter each and / or estradiol (E2) levels >15,000 pmol / mL. The dose of hCG to be administered to the patient may be from 5,000 III to 10,000 III or 150 to 500 pg recombinant hCG, for example 250 pg recombinant hCG. The use may comprise a further step of administering a GnRH antagonist starting on day 6 of stimulation.
[0026] The use may further comprise one or more or all of: retrieving (e.g. harvesting) oocyte(s); fertilizing (e.g. inseminating) the oocytes (s); allowing the fertilized oocytes to develop to the blastocyst stage; and freezing one or more (or all) blastocysts.
[0027] It will be appreciated that herein, the term “composition” is used to refer to a formulation (e.g. a single formulation) which includes both the rFSH and the menotropin. The term “product” is intended to refer to the case where the rFSH and the menotropin are formulated separately (although may be packaged together). Products according to the invention may be for use wherein the rFSH and the menotropin are administered separately, for example the rFSH is for administration in the morning and the menotropin is for administration in the afternoon or evening. Products according to the invention may be for use wherein the rFSH and the menotropin are administered together.
[0028] In some aspects, there is provided a method of treatment of infertility in a patient of age >35 (e.g., age 35 to 40, e.g., age 35-36) and bodyweight > 100 kg prior to treatment, comprising; identifying a patient of age >35 (e.g., age 35 to 40, e.g., age 35-36) and bodyweight > 100 kg prior to treatment; and administering to the patient recombinant follicle stimulating hormone (rFSH) and menotropin (human menopausal gonadotropin or hMG), wherein the rFSH is administered at a (e.g. starting) dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day; and the menotropin is administered at a dose of, or equivalent to, 200 III to 250 III (e.g. 225 IU) HP-hMG per day.
[0029] In some aspects, there is provided a method of treatment of infertility in a patient of age >35 (e.g., age 35 to 40, e.g., age 35-36) and bodyweight < 100 kg prior to treatment, comprising; identifying a patient of age >35 (e.g., age 35 to 40, e.g., age 35-36) and bodyweight < 100 kg prior to treatment; and administering to the patient recombinant follicle stimulating hormone (rFSH) and menotropin (human menopausal gonadotropin or hMG), wherein the rFSH is administered at a (e.g. starting) dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day; and the menotropin is administered at a dose of, or equivalent to, 125 IU to 175 IU (e.g. 150 IU) HP-hMG per day.In some aspects, there is provided a method of treatment of infertility in a patient of age <35 (e.g., age 25 to 34, e.g., age 30-34) and bodyweight > 100 kg prior to treatment, comprising; identifying a patient of age <35 (e.g., age 25 to 34, e.g., age 30-34) and bodyweight > 100 kg prior to treatment; and administering to the patient recombinant follicle stimulating hormone (rFSH) and menotropin (human menopausal gonadotropin or hMG), wherein the rFSH is administered at a (e.g. starting) dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g.
[0030] 12 pg) recombinant FSH per day; and the menotropin is administered at a dose of, or equivalent to, 125 IU to 175 IU (e.g. 150 IU) HP-hMG per day.
[0031] In some aspects, there is provided a method of treatment of infertility in a patient of age <35 (e.g., age 25 to 34, e.g., age 30-34) and bodyweight < 100 kg prior to treatment, comprising; identifying a patient of age <35 (e.g., age 25 to 34, e.g., age 30-34) and bodyweight < 100 kg prior to treatment; and administering to the patient recombinant follicle stimulating hormone (rFSH) and menotropin (human menopausal gonadotropin or hMG), wherein the rFSH is administered at a (e.g. starting) dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g.
[0032] 12 pg) recombinant FSH per day; and the menotropin is administered at a dose of, or equivalent to, 37.5 IU to 100 IU (e.g. 75 IU) HP-hMG per day.
[0033] It will be appreciated that the methods of treatment described above can be used in line with any aspects of the invention disclosed herein.
[0034] In some aspects, there is provided a composition comprising a recombinant follicle stimulating hormone (rFSH) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day; wherein the composition is for administration with a menotropin at a menotropin dose of, or equivalent to, 125 IU to 175 IU (e.g. 150 IU) HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 200 IU to 250 IU (e.g. 225 IU) HP-hMG per day if the patient is of weight > 100 kg. The treatment of infertility may include a step of identifying a patient of age > 35 years and bodyweight < 100 kg or > 100 kg for treatment.
[0035] In some aspects, there is provided a composition or product comprising a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition or product is for administration at a menotropin dose of, or equivalent to, 125 IU to 175 IU (e.g. 150 IU) HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 200 IU to 250 IU (e.g. 225 IU) HP-hMG per day if the patient is of weights 100 kg; wherein the composition is for administration with a recombinant follicle stimulating hormone (rFSH) at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 16 pg(e.g. 15 pg) recombinant FSH per day. The treatment of infertility may include a step of identifying a patient of age > 35 years and bodyweight < 100 kg or > 100 kg for treatment.
[0036] In some aspects, there is provided a composition comprising a recombinant follicle stimulating hormone (rFSH) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g. 12 pg) recombinant FSH per day; wherein the composition is for administration with a menotropin at a menotropin dose of, or equivalent to, 37.5 III to 100 III (e.g.
[0037] 75 III) HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 125 III to 175 III (e.g. 150 III) HP-hMG per day if the patient is of weight > 100 kg. The treatment of infertility may include a step of identifying a patient of age < 34 years and bodyweight < 100 kg or > 100 kg for treatment.
[0038] In some aspects, there is provided a composition or product comprising a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition or product is for administration at a menotropin dose of, or equivalent to, 37.5 III to 100 III (e.g. 75 III) HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 125 III to 175 III (e.g. 150 III) HP-hMG per day if the patient is of weights 100 kg; wherein the composition is for administration with a recombinant follicle stimulating hormone (rFSH) at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g. 12 pg) recombinant FSH per day. The treatment of infertility may include a step of identifying a patient of age < 34 years and bodyweight < 100 kg or > 100 kg for treatment.
[0039] In some aspects, there is provided the use of recombinant follicle stimulating hormone (rFSH) and menotropin (human menopausal gonadotropin or hMG) in the manufacture of a medicament for treatment of infertility according to any aspect described above.
[0040] Detailed Description
[0041] The present applicants have developed a mixed protocol which personalizes the starting dose of both rFSH (follitropin delta) and HP-hMG based on both age and body weight. It is expected that personalizing the dosing of rFSH and HP-hMG by considering both body weight and age could yield results similar or better to those achieved with the dosing regimen based on body weight and AMH. A further advantage of the proposed new protocol is that it avoids dosage of rFSH based on assessment of AMH level, which (a) requires a specific assay prior to treatment, and (b) is not utilised or allowed in some countries and clinics as a predictive element for ovarian response to stimulation when personalising FSH dosages.Therefore, provided herein are individualised treatments and dosing regimens constructed for use to treat infertility without requirement to test AMH level.
[0042] Definitions
[0043] Technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art of assisted reproductive technology to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies known to those of ordinary skill in the art. Any suitable materials and / or methods known to those of ordinary skill in the art can be utilized in carrying out the present invention based on the guidance provided herein. However, specific materials and methods are described. Materials, reagents and the like to which reference is made in the following description and examples are obtainable from commercial sources, unless otherwise noted.
[0044] It is to be understood, that any definitions and terms herein defined are meant to have the same meaning and purpose in any of the aspects and embodiments of the invention unless explicitly otherwise stated not to.
[0045] As used herein, the singular forms “a,” “an,” and “the” designate both the singular and the plural, unless expressly stated to designate the singular only.
[0046] As used herein, the term “about” means that the number or range so modified is not limited to the exact number or range set forth, but encompass ranges around the stated number or range as will be understood by persons of ordinary skill in the art depending on the context in which the number or range is used. Unless otherwise apparent from the context or convention in the art, “about” means up to plus or minus 10% of the particular term.
[0047] As used herein “ongoing pregnancy” refers to pregnancy with a viable foetus and detectable foetal heartbeat at 10-11 weeks gestation, e.g., at 8-9 weeks post blastocyst / embryo transfer.
[0048] As used herein “clinical pregnancy” refers to gestation and a detectable foetal heartbeat at 5-6 weeks gestation, e.g., at 3-4 weeks post blastocyst / embryo transfer.
[0049] Herein the terms “patient” and “subject” and “female” and “woman” are used interchangeably.
[0050] The term “treatment of infertility” includes treatment of infertility in a subject having tubal or unexplained infertility, including treatment of infertility in a subject having endometriosis, for example stage I or stage II endometriosis, and / or in a subject with a partner with male factor infertility. The product may be for (use in) the treatment of infertility (and / or for controlled ovarianstimulation) in a subject having endometriosis, for example in a subject having stage I or stage II endometriosis, as defined by The American Society for Reproductive Medicine (ASRM) classification system for the various stages of endometriosis, (stage IV most severe; stage I least severe) [American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67,817821.].
[0051] The serum concentration of anti-Mullerian hormone (AMH) is now established as a reliable marker of ovarian reserve. Decreasing levels of AMH are correlated with reduced ovarian response to gonadotrophins during COS. Further, high levels of AMH are a good predictor of excessive ovarian response, and an indicator of risk of OHSS. In accordance with the present disclosure, for the first (and in some cases subsequent) treatment cycle, the individual daily dose of recombinant human follicle stimulating hormone (rFSH) including a2,3- and a2,6-sialylation is determined on the basis of the woman’s serum AMH concentration and, in some embodiments, her body weight. The recombinant human follicle stimulating hormone (rFSH) including a2,3- and a2,6-sialylation dose is based on a recent determination of AMH (i.e. within the last 12 months), for example measured by the ELECSYS® AMH Plus immunoassay (Roche), or similar assays such as ACCESS AMH Advanced from Beckman Coulter or UMIPULSE G AMH from Fujirebio. Additionally or alternatively, the serum concentration of anti-Mullerian hormone (AMH) in the patient may be determined using a Beckmann-Coulter Gen 2 assay as described in Arce et al., Fertility and Sterility 99: 1644-53 (2013), or an equivalent AMH level assessed by a different method.
[0052] A subject may have a BMI >15 and BMI <40 kg / m2, for example a BMI >17.5 and BMI <38 kg / m2, for example a BMI >18 and BMI <25 kg / m2, for example a BMI >20 and BMI <25 kg / m2. Thus a product or method as described herein may be used for the treatment of infertility in a patient having BMI >15 and BMI <40 kg / m2, for example a subject having BMI >17.5 and BMI <38 kg / m2, for example a subject having BMI >18 and BMI <25 kg / m2, for example a subject having BMI >20 and BMI <25 kg / m2. Thus a product or method as described herein may be used for the treatment of infertility in a patient having BMI >17.5 and BMI <32 kg / m2. BMI may be measured by methods well known in the art to identify the patient for treatment.
[0053] The term “follicle” herein means an ovarian follicle which is a fluid-filled sac that contains an immature egg, or oocyte.
[0054] A blastocyst forms in the early development of a human (or other mammal). In humans, blastocyst formation begins about 5 days after fertilization. The use of blastocysts in (IVF) generally involves retrieval (harvesting) from the woman a number of oocytes resulting from a controlled ovarian stimulation cycle; fertilization (insemination of) one or more oocytes andculturing the fertilized egg (oocyte) for five days to form a blastocyst (i.e. allowing the fertilized oocyte to develop to the blastocyst stage); and implanting the blastocyst into the uterus.
[0055] An embryo forms in the early development of a human (or other mammal). The use of embryos in (IVF) generally involves retrieval (harvesting) from the woman a number of oocytes resulting from a controlled ovarian stimulation cycle; fertilization (insemination of) one or more oocytes and culturing the fertilized egg (oocyte) for e.g., 3 days to form an embryo (i.e. allowing the fertilized oocyte to develop to the embryo stage); and implanting the embryo into the uterus.
[0056] The term “menotropin” as used herein includes human menopausal gonadotropin (hMG). The term “highly purified menotropin” (HP-hMG) as used herein includes HP-hMG available under the trademark MENOPUR® from Ferring B.V., that contains both follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG)-driven luteinizing hormone (LH)-activity. In some examples, the hMG is a HP-hMG which includes both follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG)-driven luteinizing hormone (LH)-activity (e.g.
[0057] MENOPUR®).
[0058] The term “GnRH agonist” as used herein includes gonadotropin-releasing hormone (GnRH) agonists such as buserelin (e.g., Suprecur®), leuprorelin (leuprolide acetate, e.g., Lupron®), nafarelin (e.g., Synarel®), and triptorelin (e.g., Trelstar®).
[0059] The term “GnRH antagonist” as used herein includes gonadotropin-releasing hormone (GnRH) antagonists, such as ganirelix acetate (e.g., Orgalutran®) and cetrorelix acetate (e.g., Cetrotide®), which block the action of GnRH by competitive blocking of the GnRH receptors on pituitary gonadotropes, and thus prevent gonadotropin production / release and premature ovulation (release of eggs).
[0060] In accordance with all aspects described herein, the recombinant human follicle stimulating hormone (rFSH) including a2,3- and a2 ,6-sialylation may be human cell line-derived recombinant FSH as described in more detail below. In all aspects, the recombinant FSH including a2,3- and a2,6-sialylation may be that sold under the trademark REKOVELLE® (follitropin delta) (Ferring B.V.). In all aspects, the recombinant FSH may be administered by injection, e.g., subcutaneous injection.
[0061] As used herein, “day one of treatment”, also referred to as “day one of stimulation”, refers to the first day that the dose of recombinant FSH and menotropin is administered to the patient. Day one of treatment (stimulation) may take place on day 1 , 2 or 3, for example on day 2 or day 3, of the patient’s menstrual cycle. In other words, day one of treatment (stimulation) may be one, two or three days, for example two or three days, after the patient commences menstrual bleeding,consistent with usage of this term in clinical practice with GnRH antagonist orGnRH agonist protocols. The term “during treatment” means on a day or on days that recombinant FSH and menotropin are being administered to the patient.
[0062] In the treatments, methods and uses described herein, the administration of recombinant FSH and menotropin starts on day one of treatment and may continue for two to twenty days, for example continue for2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 days. The administration of recombinant FSH and menotropin starts on day one of treatment and may continue for four to twenty days, for example seven to thirteen days, for example nine to thirteen days, for example 10 to 13 days, for example 10 to 11 days. The dose of menotropin is the same every day, as determined by an established algorithm based on body weight and age as set out below. However, the initial daily dose of rFSH may be adjusted from the mid-follicular stage of stimulation depending on the patient’s serum estradiol (E2) level measured at the mid-follicular stage.
[0063] It will be appreciated that the mid-follicular stage of stimulation occurs typically after 4 to 6 days of stimulation, such as on the 5th, 6thor 7thday of stimulation. Therefore, the patient’s serum estradiol (E2) level may be measured during mid-follicular stage of stimulation (e.g., day 5, 6 or 7). Adjustment of the dose per day of rFSH may be made from the day after the day on which the patient’s serum estradiol (E2) level was measured. Therefore, depending on whether the patient’s serum estradiol (E2) level was measured on day 5, 6 or day 7 of stimulation; the dose per day of menotropin may be adjusted (increased or decreased) or maintained from day 6, 7 or 8 of stimulation.
[0064] As used herein “equivalent to” in relation to dosing means a dose that has the same pharmaceutical effect as the dose recited in the claim or herein. For example a dose of, or equivalent to, 12 pg per day may be the recited dose of 12 pg per day or may be a pharmaceutically equivalent dose such as a dose of 36 pg every 3 days. It will be appreciated this applies to any dose recited herein.
[0065] T reatments
[0066] The present applicants have developed a mixed protocol which personalizes the starting dose of both rFSH (follitropin delta) and HP-hMG based on both age and body weight. It is expected that personalizing the dosing of rFSH and HP-hMG by considering both body weight and age could yield results similar or better to those achieved with the dosing regimen based on body weight and AMH. A further advantage of the proposed new protocol is that it avoids dosage of rFSH based on assessment of AMH level, which (a) requires a specific assay prior to treatment, and(b) is not utilised or allowed in some countries and clinics as a predictive element for ovarian response to stimulation when personalising FSH dosages.
[0067] According to the invention in a first aspect there is provided a composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 200 III to 250 III HP-hMG per day if the patient is of weight > 100 kg. The composition or product may be for administration at a rFSH dose of 15 pg recombinant FSH per day and a menotropin dose of 125 III to 175 III HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of 200 III to 250 III HP-hMG per day if the patient is of weight > 100 kg. The composition or product may be for administration at a rFSH dose of 15 pg recombinant FSH per day and a menotropin dose of 150 III HP-hMG per day if the patient is of weight < 100 kg; ora menotropin dose of 225 III HP-hMG per day if the patient is of weights 100 kg.
[0068] The use may comprise a step of determining the age of the patient, and a step of administering the rFSH and menotropin (hMG) to a patient of age > 35 years, for example age 35 - 40 years, and or age >40 years. The treatment of infertility may include a step of identifying a patient of age > 35 years and bodyweight < 100 kg or > 100 kg for treatment.
[0069] According to the invention in a second aspect there is provided a composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g. 12 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 37.5 III to 100 III HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weight > 100 kg. The composition or product may be for administration at a rFSH dose of 12 pg recombinant FSH per day and a menotropin dose of 37.5 III to 100 III HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of 125 III to 175 III HP-hMG per day if the patient is of weight > 100 kg. The composition or product may be for administration at a rFSH dose of 12 pg recombinant FSH per day and a menotropin dose of 75 III HP-hMG per day if the patient is of weight < 100 kg; ora menotropin dose of 150 III HP-hMG per day if the patient is of weights 100 kg.
[0070] The use may comprise a step of determining the age of the patient, and a step of administering the rFSH and menotropin (hMG) to a patient of age < 34 years, for example age 28 - 34 years,for example age 30 - 33 years. The treatment of infertility may include a step of identifying a patient of age < 34 years and bodyweight < 100 kg or > 100 kg for treatment.
[0071] According to the invention in a third aspect, there is provided a composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 17.5 pg (e.g. 14 to 17 pg, e.g. 15 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 200 III to 250 III HP-hMG per day if the patient is of weights 100 kg.
[0072] The use may comprise a step of determining the age of the patient, and a step of administering the rFSH and menotropin (hMG) to a patient of age > 35 years, for example age 35 - 40 years, and or age >40 years. The treatment of infertility may include a step of identifying a patient of age > 35 years and bodyweight < 100 kg or > 100 kg for treatment.
[0073] According to the invention in a fourth aspect, there is provided a composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 14 pg (e.g. 11.5 to 13.5 pg , e.g. 12 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 37.5 III to 100 III HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weights 100 kg.
[0074] The use may comprise a step of determining the age of the patient, and a step of administering the rFSH and menotropin (hMG) to a patient of age < 34 years, for example age 28 - 34 years, for example age 30 - 33 years. The treatment of infertility may include a step of identifying a patient of age < 34 years and bodyweight < 100 kg or > 100 kg for treatment.
[0075] The following applies to all aspects of the invention.
[0076] The treatment of infertility may be by means of controlled ovarian stimulation. The treatment of infertility may be by treating a female.
[0077] Preferably, the recombinant human follicle stimulating hormone (rFSH) includes a2,3- and a2,6-sialylation. The recombinant human follicle stimulating hormone (rFSH) may be produced orexpressed in a human cell line, optionally wherein the human cell line is modified with an a2,3-sialyltransferase or an a2,6-sialyltransferase. The recombinant human follicle stimulating hormone (rFSH) may include a2,3- and a2,6-sialylation wherein 10 to 20% of the sialylation is a2,6-sialylation and 80 to 90% of the sialylation is a2,3-sialylation (e.g., follitropin delta, available from Ferring B.V.). The recombinant human follicle stimulating hormone (rFSH) may include a2,3- and a2,6-sialylation wherein 10 to 60% of the sialylation is a2,6-sialylation and 40 to 90% of the sialylation is a2,3-sialylation.
[0078] Preferably, the menotropin is highly purified menotropin (HP-hMG).
[0079] The use may further comprise a step or steps of determining the serum estradiol (E2) level of the patient during treatment / stimulation. The serum estradiol (E2) level of the patient may be determined for the purposes of monitoring the response to stimulation and subsequently adjusting the dose per day dose of menotropin and / or for the choice of triggering medication for final follicular maturation as described in more detail below. The serum estradiol (E2) levels may be determined by methods known in the art.
[0080] The composition or product may be administered from day 1 of stimulation to at least day 5, 6 or 7 of stimulation. From day 6, 7 or 8 of stimulation, the rFSH dose may be maintained, increased or decreased based on the serum estradiol (E2) level of the patient on day 5, 6 or 7 of stimulation. The composition or product may be for use wherein (a) from day 6, 7 or 8 of stimulation, the rFSH dose is (i) decreased (relative to the starting dose) by up to 3 pg (for example decreased by 1 , 2 or 3 pg) in a patient having an estradiol (E2) level of >3000 pmol / L on day 5, 6 or 7 of stimulation; or (b) from day 6, 7 or 8 of stimulation, the rFSH dose is (i) increased (relative to the starting dose) by up to 3 pg (for example increased by 1 , 2 or 3 pg) in a patient having an estradiol (E2) level of <1000 pmol / L, for example 750-999 pmol / L on day 5, 6 or 7 of stimulation; or (c) from day 6, 7 or 8 of stimulation the rFSH dose is maintained in a patient having an estradiol (E2) level of between 1000 and 3000 pmol / L on day 5, 6 or 7 of stimulation.
[0081] The rFSH dose (e.g. the dose from day 6, 7 or 8 of stimulation) may be maintained or further adjusted (further increased or further decreased). In aspects, the daily rFSH dose may be further increased (relative to the starting or previously adjusted dose) by up to 3 pg (for example increased by 1 , 2 or 3 pg) with dose increases implemented not more frequently than once every 2 days. In aspects, the daily rFSH dose may be further decreased (relative to the starting or previously adjusted dose) by up to 3 pg (for example decreased by 1 , 2 or 3 pg).In aspects of the invention, the maximum rFSH dose is, or is equivalent to, 18 pg recombinant FSH per day. In aspects of the invention, the minimum rFSH dose is, or is equivalent to, 6 pg recombinant FSH per day.
[0082] The use may comprise a further step of assessing follicular growth by ultrasonography e.g., on day 9, 10, 11, 12, 13, 14 etc. of stimulation.
[0083] The use may comprise a further step of triggering ovulation. The further step of triggering ovulation may comprise: administering hCG + / - GnRH agonist to a patient who, following stimulation, has >3 follicles of >17 mm in diameter each and estradiol (E2) levels <10,000 pmol / L; administering hCG + / - GnRH agonist to a patient who, following stimulation, has >3 follicles of >17 mm in diameter each and estradiol (E2) levels between 10,000 pmol / L and 15,000 pmol / L; or administering a GnRH agonist to a patient who, following stimulation, has >20 follicles of >12 mm in diameter each and / or estradiol (E2) levels >15,000 pmol / mL. The dose of hCG to be administered to the patient may be from 5,000 IU to 10,000 IU or 150 to 500 pg recombinant hCG, for example 250 pg recombinant hCG. The use may comprise a further step of administering a GnRH antagonist starting on day 6 of stimulation.
[0084] The use may further comprise one or more or all of: retrieving (e.g. harvesting) oocyte(s); fertilizing (e.g. inseminating) the oocytes (s); allowing the fertilized oocytes to develop to the blastocyst stage; and freezing one or more (or all) blastocysts.
[0085] It will be appreciated that herein, the term “composition” is used to refer to a formulation (e.g. a single formulation) which includes both the rFSH and the menotropin. The term “product” is intended to refer to the case where the rFSH and the menotropin are formulated separately (although may be packaged together). Products according to the invention may be for use wherein the rFSH and the menotropin are administered separately, for example the rFSH is for administration in the morning and the menotropin is for administration in the afternoon or evening. Products according to the invention may be for use wherein the rFSH and the menotropin are administered together.
[0086] In a further aspect, there is provided a method of treatment of infertility in a patient of age >35 (e.g., age 35 to 40, e.g., age 35-36) and bodyweight > 100 kg prior to treatment, comprising; identifying a patient of age >35 (e.g., age 35 to 40, e.g., age 35-36) and bodyweight > 100 kg prior to treatment; and administering to the patient recombinant follicle stimulating hormone (rFSH) and menotropin (human menopausal gonadotropin or hMG), wherein the rFSH is administered at a (e.g. starting) dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinantFSH per day; and the menotropin is administered at a dose of, or equivalent to, 200 IU to 250 IU (e.g. 225 IU) HP-hMG per day.
[0087] In a further aspect, there is provided a method of treatment of infertility in a patient of age >35 (e.g., age 35 to 40, e.g., age 35-36) and bodyweight < 100 kg prior to treatment, comprising; identifying a patient of age >35 (e.g., age 35 to 40, e.g., age 35-36) and bodyweight < 100 kg prior to treatment; and administering to the patient recombinant follicle stimulating hormone (rFSH) and menotropin (human menopausal gonadotropin or hMG), wherein the rFSH is administered at a (e.g. starting) dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day; and the menotropin is administered at a dose of, or equivalent to, 125 III to 175 III (e.g. 150 IU) HP-hMG per day.
[0088] In a further aspect, there is provided a method of treatment of infertility in a patient of age <35 (e.g., age 25 to 34, e.g., age 30-34) and bodyweight > 100 kg prior to treatment, comprising; identifying a patient of age <35 (e.g., age 25 to 34, e.g., age 30-34) and bodyweight > 100 kg prior to treatment; and administering to the patient recombinant follicle stimulating hormone (rFSH) and menotropin (human menopausal gonadotropin or hMG), wherein the rFSH is administered at a (e.g. starting) dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g.
[0089] 12 pg) recombinant FSH per day; and the menotropin is administered at a dose of, or equivalent to, 125 IU to 175 IU (e.g. 150 IU) HP-hMG per day.
[0090] In a further aspect, there is provided a method of treatment of infertility in a patient of age <35 (e.g., age 25 to 34, e.g., age 30-34) and bodyweight < 100 kg prior to treatment, comprising; identifying a patient of age <35 (e.g., age 25 to 34, e.g., age 30-34) and bodyweight < 100 kg prior to treatment; and administering to the patient recombinant follicle stimulating hormone (rFSH) and menotropin (human menopausal gonadotropin or hMG), wherein the rFSH is administered at a (e.g. starting) dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g.
[0091] 12 pg) recombinant FSH per day; and the menotropin is administered at a dose of, or equivalent to, 37.5 IU to 100 IU (e.g. 75 IU) HP-hMG per day.
[0092] It will be appreciated that the methods of treatment described above can be used in line with any aspects of the invention disclosed herein.
[0093] According to the invention in a further aspect there is provided a composition comprising a recombinant follicle stimulating hormone (rFSH) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day; wherein the composition is for administration with a menotropin at a menotropin dose of, or equivalent to, 125 IU to 175 IU(e.g. 150 III) HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 200 III to 250 III (e.g. 225 III) HP-hMG per day if the patient is of weight > 100 kg. The treatment of infertility may include a step of identifying a patient of age > 35 years and bodyweight < 100 kg or > 100 kg for treatment.
[0094] According to the invention in a further aspect there is provided a composition or product comprising a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition or product is for administration at a menotropin dose of, or equivalent to, 125 III to 175 III (e.g. 150 III) HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 200 III to 250 III (e.g. 225 III) HP-hMG per day if the patient is of weight > 100 kg; wherein the composition is for administration with a recombinant follicle stimulating hormone (rFSH) at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day. The treatment of infertility may include a step of identifying a patient of age > 35 years and bodyweight < 100 kg or > 100 kg for treatment.
[0095] According to the invention in a further aspect there is provided a composition comprising a recombinant follicle stimulating hormone (rFSH) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g. 12 pg) recombinant FSH per day; wherein the composition is for administration with a menotropin at a menotropin dose of, or equivalent to, 37.5 III to 100 III (e.g. 75 III) HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 125 III to 175 III (e.g. 150 III) HP-hMG per day if the patient is of weight > 100 kg. The treatment of infertility may include a step of identifying a patient of age < 34 years and bodyweight < 100 kg or > 100 kg for treatment.
[0096] According to the invention in a further aspect there is provided a composition or product comprising a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition or product is for administration at a menotropin dose of, or equivalent to, 37.5 III to 100 III (e.g. 75 III) HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 125 III to 175 III (e.g. 150 III) HP-hMG per day if the patient is of weight > 100 kg; wherein the composition is for administration with a recombinant follicle stimulating hormone (rFSH) at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g. 12 pg) recombinant FSH per day. The treatment of infertility may include a step of identifying a patient of age < 34 years and bodyweight < 100 kg or > 100 kg for treatment.In some aspects (for example when the use is in the treatment of infertility in a patient of age < 34 years, for example as set out in the claims appended hereto), the patient may have an AMH level of 2.1 ng / mL or greater, for example an AMH level of 2.1 ng / mL to 4 ng / mL, for example an AMH level of 2.5 ng / mL to 3.5 ng / mL. The patient may have an AMH level of 2.5 ng / mL or greater, for example an AMH level of 2.5 ng / mL to 3.5 ng / mL. The use in the treatment of infertility may include a step of identifying a patient of the specified AMH for treatment (e.g. by methods well known in the art, for example by methods discussed in Example 1 for the MARCS trial).
[0097] It will be appreciated that the pharmaceutical compositions described above represent components of the product according to other aspects of the invention and can be used in line with any aspect of the invention disclosed herein.
[0098] Menotropin and Recombinant FSH and rFSH Compositions
[0099] The methods, compositions and products described herein use recombinant human follicle stimulating hormone (rFSH). FSH comprises a 92 amino acid alpha sub-unit, also common to the other glycoprotein hormones LH and chorionic gonadotropin (CG), and a 111 amino acid beta sub-unit unique to FSH that confers the biological specificity of the hormone (Pierce and Parsons, 1981). Each sub-unit is post tra nslation al ly modified by the addition of complex carbohydrate residues. Both subunits carry 2 sites for N-linked glycan attachment, the alpha subunit at amino acids 52 and 78 and the beta sub-unit at amino acid residues 7 and 24 (Rathnam and Saxena, 1975, Saxena and Rathnam, 1976). FSH is thus glycosylated to about 30% by mass (Dias and Van Roey. 2001. Fox et al. 2001).
[0100] The glycosylation of rFSH products reflects the range of glycosyl-transferases present in the host cell line. Commercially available rFSH products derived from engineered Chinese hamster ovary cells (CHO cells) have a more limited range of glycan modifications than those found on the natural products. Examples of the reduced glycan heterogeneity found in CHO cell-derived rFSH include a lack of bisecting glucosamine and a reduced content of core fucosylation and acetyl lactosamine extensions (Hard etal., 1990). In addition, CHO cells are only able to add sialic acid at the a2,3 linkage (Kagawa etal, 1988, Takeuchi etal, 1988, Svensson etal., 1990); thus, CHO cell-derived rFSH only includes a2,3-linked sialic acid and does not include a2,6-linked sialic acid. Thus, CHO cell-derived rFSH is different from naturally produced FSH (e.g., human pituitary / serum / urinary FSH) which contains glycans with a mixture of a2,3 and a2,6-linked sialic acid (i.e., a2,3- and a2,6-sialylation), with a predominance of the former.
[0101] The present applicants have developed a human cell line-derived rFSH which is the subject of International Patent Application No. PCT / GB2009 / 000978, published as WO2009 / 127826A, andalso approved by the European Commission as REVOKELLE® (follitropin delta) (also known as FE 999049). This recombinant FSH, with a mixture of both a2,3 and a2,6-linked sialic acid (i.e., a2,3- and a2 ,6-sialylation) , was made by engineering a human cell line to express both rFSH and a2,3-sialyltransferase. The amino acid sequence of the human cell line-derived recombinant FSH which is the subject of International Patent Application No. PCT / GB2009 / 000978, published as WO2009 / 127826A (e.g., follitropin delta / FE 999049), is the native human FSH sequence, but the product has a different glycosylation pattern. The expressed product is highly acidic and carries a mix of both a2,3- and a2,6-linked sialic acids (i.e., a2,3- and a2 ,6-sialylation); the latter provided by the endogenous sialyl transferase activity. It was found that the type of sialic acid linkage, a2,3- ora2,6-, can have a dramatic influence on biological clearance of FSH. Thus REVOKELLE® (follitropin delta / FE 999049) may be more biologically appropriate compared to CHO cell-derived recombinant products that have only a2,3 linked sialic acid (Kagawa etal, 1988, Takeuchi etal, 1988, Svensson etal., 1990) and have decreased sialic acid content (Ulloa-Aguirre et al. 1995., Andersen et al. 2004).
[0102] Thus, the recombinant FSH used in accordance with the methods and products described herein may be produced or expressed in a human cell line, such as a PER.C6® cell line. The recombinant FSH may be produced or expressed in a PER.C6® cell line, a PER.C6® derived cell line ora modified PER. C6® cell line. Recombinant FSH which is produced or expressed in a PER.C6® cell line will include some a2,6-linked sialic acids (a2,6 sialylation) provided by endogenous sialyl transferase activity (of the cell line) and will include some a2,3-linked sialic acids (a2,3 sialylation) provided by endogenous sialyl transferase activity. The cell line may be modified using a2,3-sialyltransferase. The cell line may be modified using a2,6-sialyltransferase. Alternatively or additionally, the recombinant FSH may include a2,6-linked sialic acids (a2,6 sialylation) provided by endogenous sialyl transferase activity (of the cell line). Herein, the term “human-derived recombinant FSH” means recombinant FSH which is produced or expressed in a human cell line (e.g., recombinant FSH made by engineering a human cell line).
[0103] The recombinant FSH used in the methods and products described herein may include a2,3- and a2,6- sialylation. The recombinant FSH for use according to the invention may have 1% to 99% of the total sialylation being a2,3-sialylation. The recombinant FSH for use according to the invention may have 1% to 99% of the total sialylation being a2,6-sialylation. The recombinant FSH may have 1% to 50% of the total sialylation as a2, 6-sialyation, and 50% to 99% of the total sialylation as 2,3-sialyation. For example, 80% to 95%, for example 80% to 90%, for example 82% to 89%, for example 85% to 89% of the total sialylation may be a2,3-sialylation. For example, 5% to 20%, for example 10% to 20%, for example 11% to 18%, for example 11% to 15%, of the total sialylation may be a2,6- sialylation. In an example, the recombinant FSH has 5% to 20% of the total sialylation as a2, 6-sialyation, and 80% to 95% of the total sialylation as2,3-sialyation. In another example, the recombinant FSH has 50% to 80% of the total sialylation as a2, 6-sialyation, and 20% to 50% of the total sialylation as 2,3-sialyation.
[0104] Herein, by “sialylation”, it is meant the amount of sialic residues present on the recombinant FSH carbohydrate structures. Consistent with usage in the art, a2,3-sialylation means sialylation at the 2,3 position and a2,6 sialylation means sialylation at the 2,6 position. Thus “% of the total sialylation may be a 2,3 sialylation” refers to the % of the total number of sialic acid residues present in the FSH (or hCG) which are sialylated in the 2,3 position. The term “% of the total sialylation being a2 ,6-sialylation” refers to the % of the total number of sialic acid residues present in the FSH (or hCG) which are sialylated in the 2,6 position.
[0105] In all aspects, the rFSH may be present as a single isoform or as a mixture of isoforms.
[0106] The recombinant FSH and hMG can be formulated into well-known compositions for any route of drug administration, e.g., oral, rectal, parenteral, transdermal (e.g., patch technology), intravenous, intramuscular, subcutaneous (e.g., for subcutaneous injection), intracisternal, intravaginal, intraperitoneal, local (powders, ointments or drops) or as a buccal or nasal spray. A typical composition comprises a pharmaceutically acceptable carrier, such as aqueous solution, nontoxic excipients, including salts and preservatives, buffers and the like, as described in Remington’s Pharmaceutical Sciences fifteenth edition (Matt Publishing Company, 1975), at pages 1405 to 1412 and 1461 - 87, and the national formulary XIV fourteenth edition (American Pharmaceutical Association, 1975), among others. For example, the recombinant FSH, composition or pharmaceutical composition can be formulated for injection, such as for subcutaneous injection.
[0107] Examples of suitable aqueous and non-aqueous pharmaceutical carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
[0108] The composition may also comprise additives such as but not limited to preservatives, wetting agents, emulsifying agents, surfactants and dispersing agents. Antibacterial and antifungal agents can be included to prevent growth of microbes and include, for example, m-cresol, benzyl alcohol, paraben, chlorobutanol, phenol, sorbic acid, and the like. If a preservative is included, benzyl alcohol, phenol and / or m-cresol are preferred; however, the preservative is by no means limited to these examples. Furthermore, it may be desirable to include isotonic agents such as sugars, sodium chloride, amino acids and the like.For example, the composition or medicament may comprise recombinant FSH and one or more of polysorbate 20, L-methionine, phenol, and arginine hydrochloride. Such a composition may be formulated for injection, such as for subcutaneous injection. For example, the rFSH composition or medicament may be the REKOVELLE® formulation (follitropin delta with excipients phenol, polysorbate 20, L-methionine, sodium sulphate decahydrate, disodium phosphate dodecahydrate, phosphoric acid [concentrated, for pH-adjustment], sodium hydroxide [for pH-adjustment], and water for injection).
[0109] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
[0110] Injectable formulations can be supplied in any suitable container, e.g., vial, pre-filled syringe, injection cartridges, and the like.
[0111] The recombinant FSH, composition, product or medicament may be formulated for single use or for multiple use (multiple dose). If the recombinant FSH, composition, or medicament is formulated for multiple use, typically one or more preservatives is included. If a preservative is included, benzyl alcohol, phenol orm-cresol, are preferred; however, the preservative is by no means limited to these examples. The single use or multiple use formulated composition or medicament may further comprise an amino acid or combination of amino acids. Typically, the amino acid is arginine, for example added as arginine or more typically arginine hydrochloride.
[0112] The recombinant FSH, composition, product or medicament may be included in a container such as a vial, prefilled cartridge (e.g., for single administration or multiple use) or an injection device such as a “pen” for e.g., administration of multiple doses.
[0113] The recombinant FSH, composition or pharmaceutical composition may be a formulation (e.g., injectable formulation) including rFSH.
[0114] The recombinant FSH, composition, product or medicament can be supplied in any appropriate package. For example, a composition or medicament can include a number of containers (e.g., pre-filled syringes or vials) containing FSH. The syringes or vials may be packaged in a blister package or other means to maintain sterility. Any composition or medicament can optionally include instructions for using the FSH formulation.
[0115] The pH and exact concentration of the various components of the pharmaceutical composition are adjusted in accordance with routine practice in this field. See GOODMAN and OILMAN’S THE PHARMACOLOGICAL BASIS FOR THERAPEUTICES, 7thed. In a typical embodiment, therecombinant FSH, composition or medicament are supplied as compositions for parenteral administration. General methods for the preparation of the parenteral formulations are known in the art and are described in REMINGTON; THE SCIENCE AND PRACTICE OF PHARMACY, supra, at pages 780-820. The parenteral compositions can be supplied in liquid formulation or as a solid which will be mixed with a sterile injectable medium just prior to administration. The parenteral compositions may be supplied in dosage unit form for ease of administration and uniformity of dosage.
[0116] In a further aspect there is provided the use of recombinant follicle stimulating hormone (FSH) in the manufacture of a medicament for the uses as described herein.
[0117] Further aspects are illustrated in the following examples, which are not limiting in any respect.
[0118] The menotropin, e.g., human menopausal gonadotropin (hMG), used in the methods and products described herein may be highly purified menotropin. The term “highly purified menotropin” as used herein includes HP-hMG available under the trademark MENOPUR® from Ferring B.V., that contains both follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG)-driven luteinizing hormone (LH)-activity. In some examples, the hMG used in the methods and products described herein is a HP-hMG which includes both follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG)-driven luteinizing hormone (LH)-activity (e.g. MENOPUR®). In some examples, the hMG used in the methods and products described herein is the MENOPUR® HP-hMG product, which is typically provided as a lyophilized powder or pellet to be mixed with sterile diluent (e.g., 0.9% Sodium Chloride for Injection) prior to use. MENOPUR® is a powder and solvent solution for injection. The ingredients in MENOPUR® in addition to hMG are lactose, polysorbate 20, hydrochloric acid, sodium chloride, sodium hydroxide and water for injections.
[0119] Examples
[0120] The following examples use REKOVELLE® (follitropin delta), which is a recombinant FSH expressed in a PER.C6® cell line engineered by the methods disclosed in WO2013 / 020996 and WO2009 / 127826A, and MENOPUR®, which is highly purified menotropin (HP-hMG) that contains both follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG)-driven luteinizing hormone (LH)-activity.
[0121] The Marketing Authorisation holder for REKOVELLE® and MENOPUR® is Ferring Pharmaceuticals A / S of Kay Fiskers Plads 11, 2300 Copenhagen S, Denmark, and REKOVELLE® is available in the UK from Ferring Pharmaceuticals of Drayton Hall, Church Road, West Drayton, UB77PS, UK.The active substance in REKOVELLE® is follitropin delta (FE999049). REKOVELLE® is highly sialylated and includes a2,3- and a2,6- sialylation, with about 85% to 90% of the total sialylation being a2,3-sialylation and about 10% to 15% of the total sialylation being a2,6-sialylation.
[0122] REKOVELLE® is a clear and colourless solution for injection (injection). One millilitre of solution contains 33.3 micrograms of follitropin delta in each millilitre of solution. The other ingredients are phenol, polysorbate 20, L-methionine, sodium sulphate decahydrate, disodium phosphate dodecahydrate, concentrated phosphoric acid, sodium hydroxide and water for injections.
[0123] The active substance in MENOPUR® is human menopausal gonadotrophin (HMG).
[0124] MENOPUR® is a powder and solvent solution for injection. The other ingredients are lactose, polysorbate 20, hydrochloric acid, sodium chloride, sodium hydroxide and water for injections. MENOPUR® (e.g. MENOPUR® 75 IU injection, Menopur® 1200 IU Powder and solvent for solution for injection) is available in the UK from Ferring Pharmaceuticals Limited of Drayton Hall, Church Road, West Drayton, UB77PS, UK.
[0125] Example 1: Menopur and Rekovelle Combined Study (MARCS 2.0): A proposed study evaluating the effect in terms of usable blastocyst yield of individualised dosages of follitropin delta based on age and bodyweight together with highly purified human menopausal gonadotropin (HP-hMG) for controlled ovarian stimulation, compared with the MARCS study wherein follitropin delta was dosed based on AMH and bodyweight
[0126] Introduction
[0127] The original MARCS study aimed to evaluate the mean number of good-quality blastocysts obtained at day 5 and on day 6 as well as the proportion of women with ovarian hyperstimulation syndrome (OHSS) after treatment with an individualised dosing regimen of a follitropin delta and highly purified human menopausal gonadotrophin (HP-hMG) compared with treatment with personalised doses of follitropin delta used as monotherapy. In the original MARCS study the follitropin delta was dosed according to the personalized dosing algorithm developed for follitropin delta (Rekovelle), with dosing based on body weight and AMH. All patients participating in the MARCS study were treated with a fixed personalized daily subcutaneous dose of follitropin delta (REKOVELLE®, Ferring Pharmaceuticals A / S), determined by an established algorithm based on body weight and serum AMH level (Table A) which is the subject of International Patent Application No. PCT / EP2012 / 065507, published as WO2013 / 020996. Serum AMH measurements were performed at a central laboratory (CReATe Fertility Centre),using the automated Elecsys AMH immunoassay (Roche), and were determined within the last 12 months before the start of ovarian stimulation.
[0128] Table A: Calculation of daily dose of fol litropin delta based on AMH concentration
[0129] AMH concentration (pmol / L) Daily dose of follitropin delta fixed throughout stimulation
[0130] <15 12 pg
[0131] 15-16 0.19 pg / kg
[0132] 17 0.18 pg / kg
[0133] 18 0.17 pg / kg
[0134] 19-20 0.16 pg / kg
[0135] 21-22 0.15 pg / kg
[0136] 23-24 0.14 pg / kg
[0137] 25-27 0.13 pg / kg
[0138] 28-32 0.12 pg / kg
[0139] 33-39 0.11 pg / kg
[0140]
[0141] >40 0.10 pg / kg
[0142] The dose is rounded off to the nearest 0.33 micrograms to match the dosing scale on the injection pen. The maximum daily dose of follitropin delta allowed according to the personalized dosing algorithm, in both arms of the MARCS study, was 12 pg. In other words, the maximum rFSH dose in the initial MARCS trial was 12 pg. Therefore, even if according to Table A above the calculated daily dose fora patient with AMH 21 -22 pmol / L and weight 100 kg would be 15 pg, the actual dose will be still capped at 12 pg. This is because rFSH dose was determined by an established algorithm based on body weight and serum AMH level, which specifies that “the maximum daily dose for the first treatment cycle is 12 micrograms”
[0143] In the MARCS study, the HP-hMG (MENOPUR®, Ferring Pharmaceuticals A / S) was coadministered with follitropin delta to all patients at personalized initial doses according to the patient’s weight and the calculated dose of follitropin delta.
[0144] The initial daily dose of HP-hMG was:
[0145] • 75 III when the follitropin delta dose was <12 pg;
[0146] • 150 III when the follitropin delta daily dose was 12 pg and body weight was <100 kg;
[0147] • 225 III when the follitropin delta daily dose was 12 pg and body weight was >100 kg.
[0148] The aim of this new study MARCS 2.0 is to evaluate the safety and effectiveness of the new dosing regimen, which personalizes the starting dose of both follitropin delta and HP-hMG basedon both age and body weight. The inventors will compare the outcomes of ovarian stimulation, pregnancy, and safety using this new regimen, with those obtained using the original MARCS study.
[0149] It is postulated, based on the results of the first MARCS study, that personalizing the dosing of follitropin delta and HP-hMG by considering both body weight and age could yield results similar or better to those achieved with the dosing regimen based on body weight and AMH. Further, personalizing the dosing of follitropin delta and HP-hMG by considering both body weight and age, advantageously avoids dosage based on AMH, which (a) requires a specific assay prior to treatment, and (b) is not utilised or allowed in some countries and clinics as a predictive element for ovarian response to stimulation when personalisng FSH dosages.
[0150] Methods
[0151] This will be a pilot, multicenter, open label, study of 200 patients enrolled at two research sites in Canada (100 patients per site), assessing the efficacy and safety of personalized dosage of follitropin delta in combination with HP-hMG (“mixed protocol”). The study protocol will take place subject to approval by local regulatory authorities and independent ethics committees, and will be performed in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonization Guidelines for Good Clinical Practice, and local regulatory requirements. All participants will provide written, informed consent prior to undergoing any study related procedures.
[0152] Study Participants
[0153] The women enrolled in the study will be between 18-40 years of age, with a confirmed diagnosis of unexplained infertility, tubal infertility, stage l / ll endometriosis or male factor infertility, and will be undergoing their first IVF / intracytoplasmic sperm injection (ICSI) cycle, with an IVF antagonist protocol prescribed. Additional inclusion criteria will be regular menstrual cycles of 24-35 days, presence of both ovaries, use of ejaculated sperm (fresh or frozen) for fertilization, and early follicular phase FSH serum concentration <10 IU / L.
[0154] The main exclusion criteria will be endometriosis stage lll / IV, history of recurrent miscarriages, defined as >3 consecutive losses, use of hormonal treatment (except for thyroid medication) during the last menstrual cycle before enrolment in the study. The exclusion criteria are as follows:
[0155] 1- Women undergoing oocyte donation
[0156] 2- Endometriosis stage lll / IV
[0157] 3- High risk of OHSS (AMH > 35 pmol / L)4- Gynaecological haemorrhages of unknown aetiology
[0158] 5- History of recurrent miscarriages defined as > 3 consecutive losses
[0159] 6- Renal or hepatic impairment
[0160] 7- Hypersensitivity to any active ingredient or excipients in follitropin delta and / or HP-hMG 8- Tumours of hypothalamus or pituitary gland
[0161] 9- Ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome
[0162] 10- Current or history of ovarian, uterine or mammary carcinoma
[0163] 11- Use of hormonal preparations (except for 17[3-estradiol, testosterone gel, DHEA and thyroid medication)
[0164] during the last menstrual cycle
[0165] 12- Women participating in any other interventional research project
[0166] Study Procedures
[0167] All patients participating in the study will receive a fixed personalized initial daily subcutaneous dose of either 12 or 15 mcg of follitropin delta (REKOVELLE®, Ferring Pharmaceuticals A / S) based on their age. HP-hMG (MENOPUR®, Ferring Pharmaceuticals A / S) will be coadministered with follitropin delta to all patients, with the additional personalized daily subcutaneous dose of HP-hMG determined by both the follitropin delta dose and body weight, as shown in Table 1 :
[0168] Table 1
[0169] Follilrupin della HP-hMG dose
[0170] Weight < 100 kg
[0171] Age 18 - < 35
[0172] . 12 mcg
[0173] Weight > 100 kg6
[0174] Age 35 - < 40
[0175] 15 mcg
[0176] Weight < 100 kg
[0177] Age 35 - < 40
[0178] 15 mcg
[0179]
[0180] Weight > 100 kg
[0181] These doses of follitropin delta and HP-hMG in Table 1 will be administered from day 1 (day 1 of treatment / stimulation) to day 6 (day 6 of treatment / stimulation).
[0182] It should be noted that in the first MARCS study, patients who received 12 pg FSH would receive 150 IU HP-hMG if the patient was ofweight < 100 kg or 225 IU HP-hMG for patients 100 kg. This is different to MARCS 2.0. In other words, MARCS 2.0, has lower doses of HP-hMG than those used in MARCS.The response to stimulation will be monitored via serum estradiol (E2) levels and vaginal sonography. As this will be an exploratory study, adjustments in the medication regime are expected. To avoid over- or under-stimulation, participants will come to the clinic on day 6 of stimulation for estradiol (E2) measurement. Based on the E2 level, the initial follitropin delta doses set out in Table 1 will be adjusted for day 7 (day 7 of treatment / stimulation) and subsequent days as shown in Table 2:
[0183] Table 2
[0184] 1000 - 3000 No dose adjustment
[0185] |
[0186]
[0187] -> 3000- I -by 3 mcg- Note the dose adjustment takes place the day after estradiol (E2) measurement.
[0188] If the follitropin delta dose is reduced following E2 measurement at day 6, the patient must return on day 8 for E2 measurement. If on day 8 E2 level has more than doubled compared to the day 6 visit, the follitropin delta dose must be reduced by an additional 3 pg. Each time patient’s follitropin delta dose is decreased, patient must be seen 2 days after for a cycle monitoring visit.
[0189] Based on the ovarian response (which may be measured by further estradiol (E2) measurement or ultrasound), the follitropin delta dose may be further adjusted by 3 pg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator’s judgement. The minimum daily dose will be 6 pg, and the maximum daily dose will be 18 pg. HP-hMG dose is fixed and will not be adjusted.
[0190] Gonadotropin therapy will be initiated between day 2 to day 6 (inclusive) of the menstrual cycle [so day 1 of treatment / stimulation may between day 2 to day 6 (inclusive) of the patient’s menstrual cycle], A gonadotropin-releasing hormone (GnRH) antagonist will be initiated on day 6 of stimulation and continued throughout the remainder of stimulation.
[0191] The response to stimulation will be monitored via serum estradiol (E2) levels and vaginal sonography. Triggering of final follicular maturation will be performed when >3 follicles reach 17 mm in diameter, and will be based on the serum E2 level on the day of trigger according to the site’s protocol standards. For example, the choice of the triggering medication may be based on serum E2 levels before trigger: hCG 5,000-10,000 III if E2 <10,000 pmol / L; and GnRH agonist 0.2 mg (triptorelin acetate, Decapeptyl; Ferring Pharmaceuticals) if E2 > 10,000 pmol / L.In case of an excessive ovarian response on the day of trigger defined by one or more of the following criteria:
[0192] • E2 levels > 15,000 pmol / L the day of last monitoring visit before triggering
[0193] • > 14 follicles of > 14 mm the day of last monitoring visit before triggering
[0194] • More than 15 oocytes retrieved
[0195] a freeze-all strategy will be employed.
[0196] The use of a dopamine agonist (according to the local site protocol) may be considered in such cases as a preventive intervention for early OHSS.
[0197] In case of a poor ovarian response, defined as less than 3 follicles of >17 mm by day 20, the cycle will be cancelled. If a patient elects to continue with <3 follicles, they will be excluded from the study.
[0198] Oocyte retrieval will take place 36±2 hours after triggering of final follicular maturation and oocytes will be inseminated by IVF or ICS I , using ejaculated sperm by either partner or donor. All embryos will be cultured up to day 5 or 6. All fresh embryo transfers will be performed on day 5 of culture, and single-embryo transferswill be preferred.
[0199] Surplus blastocysts will be cryopreserved for future use if the grade is 3BB or higher according to the Gardner classification. Daily intramuscular progesterone will be prescribed
[0200] for luteal phase support.
[0201] Adverse events (AEs) will be recorded from the time of signing the informed consent until the end of the study, defined as ongoing pregnancy confirmed by an ultrasound around 12 weeks of gestation. If any adverse event is reported during the study visits, follow-up calls will be done by the research team until the resolution of the adverse event.
[0202] Study Outcomes
[0203] The primary endpoint of the study will be the number of usable blastocysts per treatment cycle, the number of good-quality (>3BB) blastocysts (usable blastocysts) at day 5 and day 6 of blastocyst formation.
[0204] The endpoints are set out as follows. The study endpoints include ongoing pregnancy rate, meaning that the end of the study will be around 12 weeks of gestation by ultrasound, where a positive fetal heartbeat confirms an ongoing pregnancy.
[0205] Primary Endpoint
[0206] The primary efficacy outcome of the study will be the mean number of good quality usable blastocysts (>3BB) per patient on day 5 or 6 of embryo cultureSecondary Endpoints
[0207] Proportion of women with moderate / severe, as well as early and late OHSS, and / or preventive interventions for early OHSS (will be defined in full study protocol):
[0208] Triggering with GnRH agonist
[0209] Use of dopamine agonist
[0210] Conversion of planned fresh transfer into a freeze-all
[0211] Proportion of patients with reported AEs / SAEs
[0212] Pregnancy rate based on positive p-hCG
[0213] Ongoing pregnancy rate
[0214] Cancellation rate treatment cycles before oocyte retrieval
[0215] Number of stimulation days
[0216] Number of follicles and retrieved oocytes
[0217] Fertilisation rate
[0218] Proportion of patients with upward vs downward follitropin delta dose adjustments
[0219] FSH amount (equivalized by IU) needed per usable blastocyst
[0220] 11.2. Efficacy variables
[0221] The primary efficacy variable is the number of utilizable blastocysts. Utilizable blastocyst is defined as embryo at day 5 or 6 suitable for transfer.
[0222] Blastocyst quality assessment
[0223] All embryos will be cultured to day 5 or 6 with fresh embryo transfer on day 5 or embryo freezing on day 5 or 6 based on the local site criteria for a freeze-all strategy or supernumerary embryo management. Each blastocyst will be assigned a quality score using the well known Gardner scoring system (as published in the ALPHA-ESHRE consensus 2012) and IDA scoring system (Artificial Intelligence) for classification purposes.
[0224] It is expected that personalizing the dosing of follitropin delta and HP-hMG by considering both body weight and age could yield results similar or better to those achieved with the dosing regimen based on body weight and AMH, with the advantage that there is no need to rely on AMH level to personalise the dose.
Claims
1. Claims1. A composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 200 III to 250 III HP-hMG per day if the patient is of weight > 100 kg.
2. A composition or product for use according to claim 1 wherein the composition or product is for administration at a rFSH dose of 15 pg recombinant FSH per day; and a menotropin dose of 125 III to 175 III HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of 200 III to 250 III HP-hMG per day if the patient is of weight > 100 kg.
3. A composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g. 12 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 37.5 III to 100 III HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weight > 100 kg.
4. A composition or product for use according to claim 3 wherein the composition or product is for administration ata rFSH dose of 12 pg recombinant FSH per day; and a menotropin dose of 37.5 III to 100 III HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of 125 III to 175 lUHP-hMG per day if the patient is of weight > 100 kg.
5. A composition or product for use according to any preceding claim wherein the recombinant human follicle stimulating hormone (rFSH) includes a2,3- and a2,6-sialylation.
6. A composition or product for use according to any preceding claim wherein the recombinant human follicle stimulating hormone (rFSH) is rFSH which is produced or expressed in a human cell line, optionally wherein the human cell line is modified with an a2,3-sialyltransferase or an a2,6-sialyltransferase.
7. A composition or product for use according to any preceding claim wherein the recombinant human follicle stimulating hormone (rFSH) includes a2,3- and a2,6-sialylation wherein 10 to 20% of the sialylation is a2,6-sialylation and 80 to 90% of the sialylation is a2,3-sialylation.
8. A composition or product for use according to any preceding claim wherein the recombinant human follicle stimulating hormone (rFSH) includes a2,3- and a2,6-sialylation wherein 10 to 60% of the sialylation is a2,6-sialylation and 40 to 90% of the sialylation is a2,3-sialylation.
9. A composition or product for use according to any preceding claim wherein the menotropin is highly purified menotropin (HP-hMG).
10. A composition or product for use according to any preceding claim wherein the use comprises a further step of determining the serum estradiol (E2) level of the patient during treatment / stimulation.
11. A composition or product for use according to any preceding claim wherein the composition or product is to be administered from day 1 of stimulation to at least day 5, 6 or 7 of stimulation.
12. A composition or product for use according to claim 11 wherein from day 6, 7 or 8 of stimulation, the rFSH dose is maintained, increased or decreased based on the serum estradiol (E2) level of the patient on day 5, 6 or 7 of stimulation.
13. A composition or product for use according to claim 12 wherein (a) from day 6, 7 or 8 of stimulation, the rFSH dose is (i) decreased (relative to the starting dose) by up to 3 pg (for example decreased by 1 , 2 or 3 pg) in a patient having an estradiol (E2) level of >3000 pmol / L on day 5, 6 or 7 of stimulation; or (b) from day 6, 7 or 8 of stimulation, the rFSH dose is (i) increased (relative to the starting dose) by up to 3 pg (for example increased by 1 , 2 or 3 pg) in a patient having an estradiol (E2) level of <1000 pmol / L, for example 750-999 pmol / L on day 5, 6 or 7 of stimulation; or (c) from day 6, 7 or 8 of stimulation the rFSH dose is maintained in a patient having an estradiol (E2) level of between 1000 and 3000 pmol / L on day 5, 6 or 7 of stimulation.
14. A composition or product for use according to claim 12 or claim 13 wherein the daily rFSH dose is maintained or further adjusted (further increased or further decreased), optionally wherein the daily rFSH dose is further increased (relative to the starting or previously adjusted dose) by up to 3 pg (for example increased by 1 , 2 or 3 pg) with dose increases implemented not more frequently than once every 2 days; and / or wherein the daily rFSH dose is furtherdecreased (relative to the starting or previously adjusted dose) by up to 3 pg (for example decreased by 1 , 2 or 3 pg).
15. A composition or product for use according to any preceding claim wherein the maximum rFSH dose is, or is equivalent to, 18 pg recombinant FSH per day and / or the minimum rFSH dose is, or is equivalent to, 6 pg recombinant FSH per day.
16. A product for use according to any preceding claim wherein the rFSH and the menotropin are administered separately, for example the is for administration in the morning and the menotropin is for administration in the afternoon or evening.
17. A product for use according to any preceding claim wherein the rFSH and the menotropin are administered together.
18. A composition comprising a recombinant follicle stimulating hormone (rFSH) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day; wherein the composition is for administration with a menotropin at a menotropin dose of, or equivalent to, 125 III to 175 III (e.g. 150 III) HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 200 III to 250 III (e.g. 225 III) HP-hMG per day if the patient is of weight > 100 kg.
19. A composition or product comprising a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition or product is for administration at a menotropin dose of, or equivalent to, 125 III to 175 III (e.g.150 III) HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 200 III to 250 III (e.g. 225 III) HP-hMG per day if the patient is of weight > 100 kg; wherein the composition is for administration with a recombinant follicle stimulating hormone (rFSH) at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day.
20. A composition comprising a recombinant follicle stimulating hormone (rFSH) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g. 12 pg) recombinant FSH per day; wherein the composition is for administration with a menotropin at a menotropin dose of, or equivalent to, 37.5 III to 100 III (e.g. 75 III) HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 125 III to 175 III (e.g. 150 III) HP-hMG per day if the patient is of weights 100 kg.
21. A composition or product comprising a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition or product is for administration at a menotropin dose of, or equivalent to, 37.5 III to 100 III (e.g.75 III) HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 125 III to 175 III (e.g. 150 III) HP-hMG per day if the patient is of weight > 100 kg; wherein the composition is for administration with a recombinant follicle stimulating hormone (rFSH) at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g. 12 pg) recombinant FSH per day.
22. A composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age > 35 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 17 pg (e.g. 15 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 200 III to 250 III HP-hMG per day if the patient is of weights 100 kg.
23. A composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 11.5 to 13.5 pg (e.g. 11.5 to 12.5 pg , e.g. 12 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 37.5 III to 100 III HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weights 100 kg.
24. A composition or product according to any of claims 18, 19 or 22, wherein the treatment of infertility includes a step of identifying a patient of age s 35 years and bodyweight < 100 kg or s 100 kg for treatment.
25. A composition or product according to any of claims 20, 21 or 23, wherein the treatment of infertility includes a step of identifying a patient of age < 34 years and bodyweight < 100 kg or s 100 kg for treatment.
26. A composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age s 35 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 14 to 16 pg (e.g. 15 pg) recombinant FSH per day; and amenotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weight < 100 kg ora menotropin dose of, or equivalent to, 200 III to 250 III HP-hMG per day if the patient is of weight > 100 kg; wherein the treatment of infertility includes a step of identifying a patient of age > 35 years and bodyweight < 100 kg or > 100 kg for treatment.
27. A composition or product comprising a recombinant follicle stimulating hormone (rFSH) and a menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age < 34 years, wherein the composition or product is for administration at a (e.g. starting) rFSH dose of, or equivalent to, 11 to 13 pg (e.g. 11.5 to 12.5 pg , e.g. 12 pg) recombinant FSH per day; and a menotropin dose of, or equivalent to, 37.5 III to 100 III HP-hMG per day if the patient is of weight < 100 kg or a menotropin dose of, or equivalent to, 125 III to 175 III HP-hMG per day if the patient is of weight > 100 kg; wherein the treatment of infertility includes a step of identifying a patient of age < 34 years and bodyweight < 100 kg or > 100 kg for treatment.
28. A composition or product for use according to any of claims 3, 20, 21 , 23 or 27, wherein the patient has an AMH level of 2.1 ng / mL or greater, for example an AMH level of 2.1 ng / mL to 4 ng / mL, and / or an AMH level of 2.5 ng / mL or greater, for example an AMH level of 2.5 ng / mL to 3.5 ng / mL.
